Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain

- Abbott and LISC invest more than $37 million to empower and grow diverse small businesses that provide manufacturing and essential products for healthcare companies

- Initiative supports Abbott and LISC's commitment to increase diversity in healthcare and generate jobs and strengthen economies in underinvested communities

Abbott (NYSE: ABT) and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with the tailored growth capital, loans and support they need to compete, grow and create jobs. The initiative will support greater diversity in the healthcare industry by advancing a more inclusive supply chain for Abbott and other healthcare companies, while contributing to broader economic and health equity.

In the healthcare supply chain, the small businesses that help produce diagnostics, nutrition products, medical devices and other health technologies do not reflect the diversity of the communities they serve – which reflects a broader diversity gap in businesses across America. According to the U.S. Census Bureau , only 19% of U.S. businesses are owned by people of color and 21% are owned by women, despite representing 40% and more than half the population, respectively. Owners of diverse small businesses – including people of color and women – can help drive change, but many face challenges, with 50% unable to access loans to grow their business.

The Abbott-LISC Initiative to Support Diverse Businesses in Health aims to break down barriers that prevent diverse small businesses from providing manufacturing and essential products in healthcare. By providing targeted support, Abbott and LISC are working to build a stronger, more diverse healthcare supply chain, as well as healthier local economies and communities.

"We're committed to tearing down the barriers that diverse small-business owners often face, and to building a more inclusive supply chain in healthcare," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our new initiative with LISC takes real, pragmatic steps to make that happen."

"This partnership is a shared investment in the future of our communities and the strength of our supply chains," said LISC CEO Lisa L. Glover . "We're proud to partner with Abbott to deliver capital and technical services that enhance the infrastructure for small business growth, so owners from diverse backgrounds are better able to compete for contracts, hire more staff, and fuel economic opportunity in the communities where they operate."

Targeted Support for Diverse Small Businesses
Abbott is contributing $25 million for the initiative, including $12.5 million in loan capital and $12.5 million in grants to LISC to provide investment funding and targeted support. LISC is matching the investment with an additional $12.5 million in loan capital. This funding will support diverse small businesses in three ways:

  1. Growth capital: With Abbott grant support, LISC will provide interest-free capital to help businesses overcome hurdles to expansion, such as investing in management systems to comply with regulatory and environmental requirements. Businesses will repay LISC if and when they meet certain growth targets.
  2. Business loans: Abbott and LISC funding will provide flexible, affordable loans with terms that would not typically be available through conventional lenders.
  3. Technical assistance: An Abbott grant will support LISC in providing customized support to businesses accessing capital and loans through the initiative, including help with fulfilling investment and loan requirements and identifying and addressing specific business barriers to growth.

Eligible small businesses are those that are majority owned by people of color (including Black, Latino, Asian and Native American business owners), women, veterans, people with disabilities, people who identify as LGBTQ and other historically underrepresented groups in the U.S. with more than two years in operation and an ability to deploy capital toward business improvements and growth. To qualify, businesses should focus on manufacturing and essential business-to-business products that support the production of diagnostics, nutrition products, medical devices and other health technologies.

Collaboration Part of Broader Work to Advance Diversity, Equity, Opportunity
This joint initiative supports Abbott's 2030 Sustainability Plan , which aims to advance health access and equity through partnership and build a diverse, resilient and responsible supply chain – with specific targets to increase overall spending with diverse and small businesses 50% by 2030 and with Black- and women-owned businesses 150% by 2025. This work complements Abbott's ongoing commitment to address broader health equity challenges, including increasing diversity in clinical trials , creating opportunities in STEM for women and underrepresented groups, and empowering communities to break down social and economic barriers to better health.

The work also supports LISC's Project 10X , which bridges racial health, wealth and opportunity gaps throughout the country. The initiative helps break down historical and systemic barriers by investing in businesses, community organizations, developers and projects that are driven by and for communities of color.

To learn more about this initiative, funding eligibility and opportunities, see Abbott's site and LISC's site .

About LISC
LISC is one of the country's largest community development organizations, helping forge vibrant, resilient communities across America. We work with residents and partners to close systemic gaps in health, wealth and opportunity and advance racial equity so that people and places can thrive. Since our founding in 1979, LISC has invested $24 billion to create more than 436,320 affordable homes and apartments and develop 74.4 million square feet of retail, community and educational space.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .

Cision View original content: https://www.prnewswire.com/news-releases/abbott-and-lisc-team-up-to-address-diversity-and-equity-gaps-in-the-healthcare-industry-supply-chain-301513452.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×